---
title: "Immune biomarkers linked to response and resistance with ipilimumab plus nivolumab in mCRPC"
id: "pubmed-42873849"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42873849"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42873849/"
doi: "10.1126/sciadv.aee8730"
published_at: "2026-10-16T00:00:00.000Z"
evidence_level: "Clinical Trial, Phase II"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Immune biomarkers linked to response and resistance with ipilimumab plus nivolumab in mCRPC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42873849
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42873849/)
- **DOI:** [10.1126/sciadv.aee8730](https://doi.org/10.1126%2Fsciadv.aee8730)
- **Published At:** 2026-10-16T00:00:00.000Z
- **Evidence Rating:** Clinical Trial, Phase II
## Executive GIST (TL;DR)
- The PubMed record describes a clinical trial report titled “Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer.” - The paper was published in Sci Adv (2026 Oct 16); DOI 10.1126/sciadv.aee8730 and has PMID 42873849 and PMCID PMC13666023. - Investigators include multi-center academic and industry coauthors; lead affiliation listed is The University of Texas MD Anderson Cancer Center and collaborators include the Parker Institute for Cancer Immunotherapy and others. - The study focus, as indicated by the title, is immune biomarker correlates of clinical **response** and **resistance** to combined checkpoint blockade with **ipilimumab** and **nivolumab** in **metastatic castration-resistant prostate cancer** (mCRPC). - The PubMed entry identifies the article as a Clinical Trial, but the abstract text, cohort size, endpoints, biomarker assays, statistical results, and dosing regimen are not present in the PubMed record excerpt provided here. - The source did not report specific methodology, numeric outcomes, safety data, or detailed biomarker findings in the available record; the full text must be consulted for those data. - Because the PubMed entry contains metadata only (title, authors, journal, identifiers), clinical interpretation must await the full article; unanswered questions include which biomarkers were evaluated, which assays were used, and which markers associated with benefit or resistance. - Readers are directed to the DOI and PMCID for the full text; the PubMed record alone does not permit extraction of trial results or conclusions.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42873849/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42873849%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42873849/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42873849/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42873849/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42873849/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42873849/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42873849/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42873849%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42873849%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42873849/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42873849/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42873849/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42873849/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.science.org-pb-assets-images-logos-pubmed-sciadv.gif) Atypon ](https://pubmed.ncbi.nlm.nih.gov/www.science.org/doi/10.1126/sciadv.aee8730?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42873849/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42873849/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42873849/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42873849/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42873849/#conflict-of-interest) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42873849/#figures) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42873849/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42873849/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42873849/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42873849/#substances) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42873849/#linkout) Title & authors Abstract Conflict of interest statement Figures References Publication types MeSH terms Substances LinkOut - more resources Clinical Trial Sci Adv Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci+Adv%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci+Adv%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42873849/) . 2026 Oct 16;12(42):eaee8730. doi: 10.1126/sciadv.aee8730. Epub 2026 Oct 14. # Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer [Apostolia M Tsimberidou](https://pubmed.ncbi.nlm.nih.gov/?term=Tsimberidou+AM&cauthor_id=42873849)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-1 "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Christopher R Cabanski](https://pubmed.ncbi.nlm.nih.gov/?term=Cabanski+CR&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Alexandra Drakaki](https://pubmed.ncbi.nlm.nih.gov/?term=Drakaki+A&cauthor_id=42873849)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-3 "University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA."), [Danny N Khalil](https://pubmed.ncbi.nlm.nih.gov/?term=Khalil+DN&cauthor_id=42873849)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-4 "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA."), [Bilal A Siddiqui](https://pubmed.ncbi.nlm.nih.gov/?term=Siddiqui+BA&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Sreyashi Basu](https://pubmed.ncbi.nlm.nih.gov/?term=Basu+S&cauthor_id=42873849)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-6 "James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-7 "Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Kwame Okrah](https://pubmed.ncbi.nlm.nih.gov/?term=Okrah+K&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Diane M Da Silva](https://pubmed.ncbi.nlm.nih.gov/?term=Da+Silva+DM&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Shikha Gautam](https://pubmed.ncbi.nlm.nih.gov/?term=Gautam+S&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Farah A Alayli](https://pubmed.ncbi.nlm.nih.gov/?term=Alayli+FA&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Mike Schachter](https://pubmed.ncbi.nlm.nih.gov/?term=Schachter+M&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Justin Fairchild](https://pubmed.ncbi.nlm.nih.gov/?term=Fairchild+J&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Wai Chin Foo](https://pubmed.ncbi.nlm.nih.gov/?term=Chin+Foo+W&cauthor_id=42873849)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-8 "Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Silvia Boffo](https://pubmed.ncbi.nlm.nih.gov/?term=Boffo+S&cauthor_id=42873849)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-9 "Bristol Myers Squibb, New York, NY, USA."), [Jamie Arnott](https://pubmed.ncbi.nlm.nih.gov/?term=Arnott+J&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Ute Dugan](https://pubmed.ncbi.nlm.nih.gov/?term=Dugan+U&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Sumit K Subudhi](https://pubmed.ncbi.nlm.nih.gov/?term=Subudhi+SK&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Padmanee Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+P&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-6 "James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-7 "Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#full-view-affiliation-10 "Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.") Affiliations Expand ### Affiliations * 1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 2 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. * 3 University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. * 4 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. * 5 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 6 James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 7 Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 8 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 9 Bristol Myers Squibb, New York, NY, USA. * 10 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * PMID: **42873849** * PMCID: [ PMC13666023 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13666023/) * DOI: [ 10.1126/sciadv.aee8730 ](https://doi.org/10.1126/sciadv.aee8730) Item in Clipboard Clinical Trial # Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer Apostolia M Tsimberidou et al. Sci Adv. 2026. Show details Display options Display options Format Abstract PubMed PMID Sci Adv Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci+Adv%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci+Adv%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42873849/) . 2026 Oct 16;12(42):eaee8730. doi: 10.1126/sciadv.aee8730. Epub 2026 Oct 14. ### Authors [Apostolia M Tsimberidou](https://pubmed.ncbi.nlm.nih.gov/?term=Tsimberidou+AM&cauthor_id=42873849)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-1 "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Christopher R Cabanski](https://pubmed.ncbi.nlm.nih.gov/?term=Cabanski+CR&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Alexandra Drakaki](https://pubmed.ncbi.nlm.nih.gov/?term=Drakaki+A&cauthor_id=42873849)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-3 "University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA."), [Danny N Khalil](https://pubmed.ncbi.nlm.nih.gov/?term=Khalil+DN&cauthor_id=42873849)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-4 "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA."), [Bilal A Siddiqui](https://pubmed.ncbi.nlm.nih.gov/?term=Siddiqui+BA&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Sreyashi Basu](https://pubmed.ncbi.nlm.nih.gov/?term=Basu+S&cauthor_id=42873849)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-6 "James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-7 "Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Kwame Okrah](https://pubmed.ncbi.nlm.nih.gov/?term=Okrah+K&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Diane M Da Silva](https://pubmed.ncbi.nlm.nih.gov/?term=Da+Silva+DM&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Shikha Gautam](https://pubmed.ncbi.nlm.nih.gov/?term=Gautam+S&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Farah A Alayli](https://pubmed.ncbi.nlm.nih.gov/?term=Alayli+FA&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Mike Schachter](https://pubmed.ncbi.nlm.nih.gov/?term=Schachter+M&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Justin Fairchild](https://pubmed.ncbi.nlm.nih.gov/?term=Fairchild+J&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Wai Chin Foo](https://pubmed.ncbi.nlm.nih.gov/?term=Chin+Foo+W&cauthor_id=42873849)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-8 "Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Silvia Boffo](https://pubmed.ncbi.nlm.nih.gov/?term=Boffo+S&cauthor_id=42873849)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-9 "Bristol Myers Squibb, New York, NY, USA."), [Jamie Arnott](https://pubmed.ncbi.nlm.nih.gov/?term=Arnott+J&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Ute Dugan](https://pubmed.ncbi.nlm.nih.gov/?term=Dugan+U&cauthor_id=42873849)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-2 "Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA."), [Sumit K Subudhi](https://pubmed.ncbi.nlm.nih.gov/?term=Subudhi+SK&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."), [Padmanee Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+P&cauthor_id=42873849)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-5 "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-6 "James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-7 "Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.")[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42873849/#short-view-affiliation-10 "Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.") ### Affiliations * 1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 2 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. * 3 University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. * 4 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. * 5 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 6 James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 7 Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 8 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * 9 Bristol Myers Squibb, New York, NY, USA. * 10 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. * PMID: **42873849** * PMCID: [ PMC13666023 ](https://pmc.ncbi.nlm.ni
## Related Clinical Research

- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Spatial transcriptomics links lipid and mitochondrial metabolism to T cell exclusion in esophageal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-spatial-transcriptomic-sequencing-identifies-lipid-metabolism-and-mitochondrial.md)
- [Targeted and Immune Therapies for Renal Cell Carcinoma: Molecular Drivers and Clinical Trial Evide](https://medichelpline.com/clinical-feed/pubmed-42885310.md) (DOI: 10.3892/mmr.2026.14041)
- [Real-world outcomes with nivolumab-relatlimab in advanced melanoma: multicenter Israeli study](https://medichelpline.com/clinical-feed/pubmed-42735459.md) (DOI: 10.1016/j.ejca.2026.117047)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.